A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
The Netherlands- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Dr. H. Van Der Hoffplein 1, 6162 BG Geleen, The Netherlands
Zuyderland Medisch Centrum Stichting in Geleen, The Netherlands specialises in clinical trials of conditions such as Crohn's disease, Plasma cell myeloma, Multiple sclerosis, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.
At Zuyderland Medisch Centrum Stichting, research in neoplasms and blood cancers focuses on improving treatment outcomes for patients with a wide range of solid tumors and hematologic malignancies. The studies explore new combinations and treatment strategies for cancers such as breast cancer, non-small cell lung cancer, gastric cancer, urothelial cancer, melanoma, and multiple forms of leukemia and lymphoma.
These trials reflect a strong focus on refining cancer care through more effective and personalized treatment approaches.
Clinical research in nervous system diseases is especially active in multiple sclerosis, with studies covering relapsing, progressive, and primary progressive disease forms. The work aims to better control disease activity, slow disability progression, and assess the long-term safety and effectiveness of treatments used in everyday care.
This area highlights the site’s interest in both new and ongoing strategies for people living with chronic neurological disease.
Research in digestive system diseases includes studies for ulcerative colitis and Crohn’s disease, with attention to symptom control, endoscopic response, and longer-term safety of treatment options. The goal is to improve everyday disease management for people with chronic intestinal inflammation.
These studies support more effective and better-tolerated care for patients with long-standing gastrointestinal disease.
The site also conducts research across male urogenital diseases and cardiovascular and kidney-related conditions, including studies in metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and chronic kidney disease. This work aims to improve survival, delay progression, and better manage major complications.
These trials show a broad interest in conditions that often require coordinated, long-term internal medicine care.
Research in hormonal diseases and reproductive and urinary physiological phenomena includes studies on hypothyroidism, polycystic ovary syndrome, and treatment-related fatigue. The focus is on improving symptoms, quality of life, and the day-to-day impact of chronic endocrine disorders.
At this hospital-based research site, these studies aim to make chronic hormone-related conditions easier to live with.
Work in musculoskeletal diseases and environment and public health includes research on preventing venous thromboembolism after joint replacement, alongside studies that look at broader care organization and treatment safety. The aim is to improve prevention strategies and support safer recovery for patients.
These trials add a practical, prevention-focused dimension to the research portfolio at Zuyderland Medisch Centrum Stichting.
More sites in GeleenThe Netherlands
Clinical trials currently enrolling participants at this site.
The NetherlandsOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
The NetherlandsA Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis
The NetherlandsStudy of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease
The NetherlandsAdjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC
The NetherlandsRamantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant
The NetherlandsRituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia
The NetherlandsA study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
The NetherlandsA Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
The NetherlandsStudy of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma
The NetherlandsStudy on Letrozole and Gonadotropins for Women with Polycystic Ovary Syndrome (PCOS) to Improve Live Birth Rates
The NetherlandsStudy on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease
The NetherlandsMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.